Bluejay Diagnostics BJDX
- Market cap
- $592K
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Bluejay Diagnostics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $1.4M+1% | $1.3M−3% | $1.3M−2% | $1M−38% | $551.7K−61% | $554K−57% | $784.8K−41% | $889.9K−14% | $785.6K+42% | $586.1K+6% | $811.8K+3% | $1.4M+62% |
| SG&A | $963.5K+560% | $1.4M+22% | $1.1M+639% | $862.8K−30% | $810K−16% | $930.6K−33% | $1.1M+1% | $1.1M+27% | n/a | n/a | $1.1M+2% | $911.3K−17% |
| −$2.3M−17% | −$2.4M−3% | −$2.4M−9% | −$1.9M−35% | −$1.4M−42% | −$1.5M−38% | −$1.9M−22% | −$2M+5% | −$1.6M+19% | −$1.5M−2% | −$1.9M+3% | −$2.3M+18% | |
| Interest expense | n/a | n/a | n/a | $626.5K | $190.6K | $729 | n/a | $222−100% | $200−100% | $187−74% | n/a | n/a |
| Net income | −$2.3M−22% | −$2.3M−4% | −$2.3M−8% | −$2.5M−12% | −$1.5M−36% | −$1.4M−38% | −$1.9M−20% | −$2M−21% | −$1.6M+8% | −$1.4M−0% | −$1.9M+3% | −$2.3M+19% |
| −$13336.00−29% | −$11904.00−21% | −$6316.16−60% | −$4098.56−77% | −$1231.04−91% | −$43.68−100% | −$53.84−99% | −$22.56−99% | −$16.16−99% | −$6.28−86% | −$7.80−86% | −$4.48−80% | |
| 172+10% | 194+23% | 369+132% | 604+278% | 11.9K+6831% | 32.8K+16828% | 34.6K+9293% | 86.7K+14255% | 98.4K+724% | 228K+596% | 246.2K+611% | 519.8K+500% |
EPS, diluted: 13 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY20 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q1 FY21: share-days: the 6-month average less the second quarter's. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x4). Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x4).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Bluejay Diagnostics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BJDXBluejay Diagnostics | $592K | n/m | n/a | n/m | n/m | n/m | |
| VJETFlyte Aviation | $846.1K | n/m | n/a | 0.4× | +219% | n/m | |
| PFSAProfusa | $394.3K | n/m | n/a | n/m | n/m | n/m | |
| IVFINVO Fertility | $1.1M | n/m | n/a | 0.2× | +14% | −70.2% | |
| BBLGBone Biologics | $1.3M | n/m | n/a | n/m | n/m | n/m | |
| TNONTenon Medical | $1.3M | n/m | n/a | 0.2× | +80% | n/m | |
| AMIXAutonomix Medical | $1.6M | n/m | n/a | n/m | n/m | n/m | |
| NXGLNexgel | $1.8M | n/m | n/a | n/m | n/m | n/m | |
| ADGMAdagio Medical | $1.9M | n/m | n/a | n/a | n/m | n/a | |
| GCTKGlucotrack | $172.8K | n/m | n/a | n/m | n/m | n/m | |
| XAIRBeyond Air | $2.1M | n/m | n/a | 0.3× | +61% | n/m | |
| Peer median | $1.3M | n/a | n/a | 0.3× | +70% | −70.2% |
More on Bluejay Diagnostics
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .